Literature DB >> 26393881

Lymph node ratio is a prognostic factor for non-small cell lung cancer.

Guangyuan Sun1, Lei Xue1, Mingdong Wang1, Xuewei Zhao1.   

Abstract

The lymph node ratio (LNR) is defined as the number of pathologically positive LNs divided by the number of LNs examined. Some studies reported that high LNR was significantly associated with poor survival of non-small cell lung cancer (NSCLC). However, other studies could not confirm this result. PubMed, Embase, and the Cochrane Register of Controlled Trials were searched for relevant studies published up to July 2015. Primary outcome was the relationship between LNR and disease-specific survival (DSS) and overall survival (OS). Twelve studies with 25138 NSCLC patients were included in this meta-analysis. Higher LNR was significantly associated with decreased OS (HR = 1.93; 95% CI 1.64 - 2.28; P < 0.00001) and DSS (HR = 1.82; 95% CI 1.55 - 2.14; P < 0.00001). In the subgroup analysis, N1 stage NSCLC patients with higher LNR also showed decreased OS (HR = 1.60; 95% CI 1.25 - 2.28; P = 0.0002) and DSS (HR = 1.82; 95% CI 1.55 - 2.21; P < 0.0001). This meta-analysis indicated that LNR was an independent predictor of survival in patients with NSCLC.

Entities:  

Keywords:  association; lymph node ratio; meta-analysis; non-small cell lung cancer

Mesh:

Year:  2015        PMID: 26393881      PMCID: PMC4741811          DOI: 10.18632/oncotarget.5669

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

The long-term survival of non-small cell lung cancer (NSCLC) after surgical resection remains low due to the complex biological characteristics and high recurrence and metastasis [1]. Five-year survival rates for surgically resectable NSCLC are still unsatisfactory and range from 19% for stage IIIA to 63% for stage IA [2]. Therefore, the identification of predictive and/or prognostic markers is important to stratify patients with resected NSCLC and select high-risk patients who should receive aggressive adjuvant chemotherapy. The lymph node ratio (LNR), defined as the number of pathologically positive LNs divided by the number of LNs examined, has been reported as a useful prognostic metric. LNR incorporates both the number of pathologically positive LNs and the number of LNs examined. Some studies reported that high LNR was significantly associated with poor survival. However, other studies could not confirm this result [3-14]. Thus, the result is still controversial. We performed this meta-analysis to assess the relationship between LNR and prognosis of NSCLC.

RESULTS

Eligible studies

The process of identifying studies is shown in Figure 1. A total of 18 publications were identified in the initial search. Based on screening of titles or abstracts, 3 records were excluded. Full text articles were retrieved only for 15 publications and assessed for eligibility. Of these 15 publications, 3 publications were excluded. Finally, 12 studies were included in this meta-analysis.
Figure 1

The selection of included studies

Twelve studies with 25138 NSCLC patients were included in this meta-analysis. These studies were conducted ranged from 2011 to 2015. The median follow-up duration ranged from 1.8 to 17 years. The quality score ranged from 6 to 9. The characteristics of included studies were showed in Table 1.
Table 1

Characteristics of the studies included in this meta-analysis

First authorYearAge (years)T stageN stageCase number (n)Follow-up duration (years)Disease-specific survival reportedOverall survival reportedAdjustScores
Jonnalagadda2011<65T1-T3N1400415YesYesage, sex, race, histology, tumor site and status, type of surgery, and receipt of radiation therapy8
Wisnivesky2011>65T1-T3N1168215YesYesage, sex, race/ethnicity, marital status, estimated income, comorbidities, histology, tumour status and location, type of surgery and use of chemotherapy or radiation therapy.8
Matsuguma2012NAT1-T3N0-N265117NoYesage, gender, histology, pathological T status, surgical type, postoperative chemotherapy, and postoperative radiotherapy.7
Nwogu2012NANAN0-N250124YesYesage, race, sex, tumor size, and histologic grade of the tumor8
Wang201131-78T1-T3N1-N230110YesYesHistologic type, stage, smoking, No. of involved nodes7
Li201364T1-T3NA2065NoYesdifferent nodal involvement pattern, the ratio of the number of positive LNs to the total number of LNs removed, number of LNs involved, patient age, sex, history of smoking, pathologic type, type of resection, VPI, lymph vascular invasion, and tumor size6
Qiu201359T1-T3N0-N24803YesYesage, sex, smoking status, location of tumor, histology, pathology T stage, pathology N stage, surgical procedure, chemotherapy, metastatic lymph node6
Taylor2013NANAN1-N211433.7YesNoage, sex, use of preoperative radiation, use of preoperative chemotherapy, preoperative ECOG status, pathologic tumor stage, N stage, T stage, total lymph nodes removed7
Urban201366T1-T4N1-N2113241.8NoYesage, sex, race, grade, histology, laterality, surgery, pathology T stage, pathology N stage8
Hsieh201460.2T0-T3N21082.4YesYesT stage, Angiolymphatic invasion, Perineural invasion, operation6
Wu201434-83T1-T3N1755.5YesYesSex, smoking, adjuvant therapy, angiolymphatic invasion, histology6
Renaud201558.5T1-T4N0-N21522.7NoYesAdjuvant treatment, Extracapsular spread, pathology T stage, pathology N stage, Type of surgery, Charlson comorbidity index7

NA, not available.

NA, not available.

Quantitative data synthesis

As shown in Figure 2, higher LNR was significantly associated with decreased OS (HR = 1.93; 95% CI 1.64 - 2.28; P < 0.00001). In the subgroup analysis, N1 stage NSCLC patients with higher LNR was also associated with decreased OS (HR = 1.60; 95% CI 1.25 - 2.28; P = 0.0002). As shown in Figure 3, higher LNR was significantly associated with decreased DSS (HR = 1.82; 95% CI 1.55 - 2.14; P < 0.00001). In the subgroup analysis, N1 stage NSCLC patients with higher LNR was also associated with decreased DSS (HR = 1.82; 95% CI 1.55 - 2.21; P < 0.0001). In the subgroup analysis by sample size, both studies with large scale and small scale showed similar results (Table 2).
Figure 2

Meta-analysis of the association between LNR and OS

Figure 3

Meta-analysis of the association between LNR and DSS

Table 2

Results of the meta-analysis

No. of studiesTest of associationModelHeterogeneity
HR (95% CI)ZP Valueχ2P ValueI2 (%)
Overall survival111.93 (1.64-2.28)7.83<0.00001R16.220.0938.0
 N131.60 (1.25-2.05)3.730.0002R1.450.490.0
 Large scale (n>1000)41.60 (1.36-1.88)5.73<0.00001R3.010.390.0
 Small scale (n<1000)72.32 (1.91-2.82)8.55<0.00001R4.760.570.0
Disease-specific survival81.82 (1.55-2.14)7.31<0.00001R4.360.740.0
 N131.70 (1.31-2.21)3.98<0.0001R1.540.460.0
 Large scale (n>1000)41.75 (1.42-2.15)5.32<0.00001R1.860.600.0
 Small scale (n<1000)41.93 (1.50-2.50)5.04<0.00001R2.160.540.0

R, random-effects model.

R, random-effects model. Sensitivity analysis did not change the results of this meta-analysis (Figures 4 and 5). The funnel plot and Egger's test were performed for the overall comparison. No obvious visual asymmetry was observed in funnel plots (Figures 6 and 7), and the P values of the Egger's test were greater than 0.05.
Figure 4

Sensitivity analysis of the association between LNR and OS

Figure 5

Sensitivity analysis of the association between LNR and DSS

Figure 6

Funnel plot of the association between LNR and OS

Figure 7

Funnel plot of the association between LNR and DSS

DISCUSSION

This meta-analysis of 12 observational studies showed that NSCLC patients with higher LNR had worse outcome. NSCLC patients with N1 stage showed similar results. The studies suggested that LNR could be a prognostic factor in other cancers. For example, Chen et al. showed that a staging system based on LNR may have better prognostic stratification of patients with esophageal squamous cell carcinoma than the current TNM system [15]. Liao et al. indicated that LNR was an important prognostic factor with regard to OS for patients with node-positive breast cancer [16]. Kutlu and colleagues suggested that LNR is an effective tool to predict survival in a western gastric cancer patient population [17]. Zhan and colleagues indicated that LNR was an independent adverse prognostic factor for pancreatic cancer [18]. In addition, Fleming et al. suggested that LNR appears to be a useful tool to identify patients with worse prognosis in node-positive early stage cervical cancer [19]. Recent studies also investigated whether patients with high LNR should receive radiotherapy. Urban et al. indicated that the survival benefit associated with postoperative radiotherapy seemed to be limited to patients with high LNR [11]. However, whether patients with high LNR should receive adjuvant chemotherapy is needed to be investigated in the future. Our study had some advantages. First, this is the first meta-analysis about LNR and outcome of NSCLC. Second, the statistic power is well enough for this meta-analysis. However, this study also had several limitations. First, all the included studies were observational retrospective investigations. Second, lacking of the original data of the eligible studies limited the evaluation of the effects of LNR on different populations, such as smoker and non-smoker, adenocarcinoma and squamous cell carcinoma. Third, although we performed an extensive review of the main electronic databases, we cannot be sure to have included all relevant studies. In conclusion, this meta-analysis indicated that LNR was an independent predictor of survival in patients with NSCLC.

MATERIALS AND METHODS

Publication search

PubMed, Embase, and the Cochrane Register of Controlled Trials were searched for relevant studies published up to July 2015. The following terms were used: (“NSCLC” or “lung cancer” or “non-small cell lung cancer”) and (“lymph node ratio” or “LNR”). The MeSH terms were used: “Lung Neoplasms” or “Carcinoma, Non-Small-Cell Lung”. No language restrictions were imposed. References from relevant articles, including review papers, were also reviewed.

Selection and exclusion criteria

Studies were included in the meta-analysis if they fulfilled the following inclusion criteria: 1) study design: cohort studies; 2) population: patients with NSCLC; 3) primary outcome: the relationship between LNR and disease-specific survival (DSS) and overall survival (OS). Abstract, case reports, review articles, experimental studies and commentary articles were excluded. Eighteen studies were searched from PubMed, Embase, and the Cochrane Register of Controlled Trials. However, four duplicate studies and two studies without of survival were excluded. At last, twelve studies were selected for this meta-analysis.

Data extraction

Two investigators reviewed and extracted information independently from selected publications in accordance with the above mentioned inclusion and exclusion criteria. Any conflicts over study/data inclusion were settled by a discussion between the investigators. The following items were extracted from each study if available: first author, year of publication, age, T stage, N stage, sample size, follow-up years, and covariates.

Qualitative assessment

Two authors completed the quality assessment independently. The Newcastle-Ottawa Scale (NOS) was used to evaluate the methodological quality, which scored studies by the selection of the study groups, the comparability of the groups, and the ascertainment of the outcome of interest. We considered a study awarded 0-3, 4-6, or 7-9 as a low-, moderate-, or high-quality study, respectively.

Statistical analysis

We estimated the hazard ratio (HR) with 95% confidence interval (CI) for primary outcome. The multivariable-adjusted HRs with 95% CIs were pooled in this analysis. Heterogeneity of the combined studies was assessed with Cochran's Q-statistic test and I2 test. The P value of Cochran's Q-statistic of below 0.05, was considered statistically significant heterogeneity. The I2 test provides a measure of the degree of heterogeneity in the results. Typically, values of 0∼25% are considered to represent no heterogeneity, 25∼50% to modest heterogeneity, 50∼75% to large heterogeneity and 75∼100% to extreme heterogeneity. A random effects model was applied. Subgroup analysis and sensitivity analysis were performed. Sensitivity analyses were conducted to assess the strength of our findings by excluding one study at a time. Publication bias was investigated by Egger's test. All statistical analyses were performed with STATA 11.0 software.
  19 in total

1.  Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.

Authors:  Matthew D Taylor; Damien J LaPar; Christopher J Thomas; Matthew Persinger; Edward B Stelow; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  Ann Thorac Surg       Date:  2013-08-30       Impact factor: 4.330

2.  Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.

Authors:  Stéphane Renaud; Pierre-Emmanuel Falcoz; Anne Olland; Jérémie Reeb; Nicola Santelmo; Gilbert Massard
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-11-20

3.  Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.

Authors:  Nicole D Fleming; Michael Frumovitz; Kathleen M Schmeler; Ricardo dos Reis; Mark F Munsell; Patricia J Eifel; Pamela T Soliman; Alpa M Nick; Shannon N Westin; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2014-11-18       Impact factor: 5.482

4.  Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer.

Authors:  Chen-Ping Hsieh; Jui-Ying Fu; Yun-Hen Liu; Cheng-Ta Yang; Ming-Ju Hsieh; Ying-Huang Tsai; Yi-Cheng Wu; Ching-Yang Wu
Journal:  Biomed J       Date:  2015 Jul-Aug       Impact factor: 4.910

5.  Prognostic value of the lymph node ratio in breast cancer subtypes.

Authors:  Guo-Shiou Liao; Yu-Ching Chou; Mehra Golshan; Huan-Ming Hsu; Zhi-Jie Hong; Jyh-Cherng Yu; Ji-Hong Zhu
Journal:  Am J Surg       Date:  2015-06-03       Impact factor: 2.565

6.  Lymph node ratio-based staging system for esophageal squamous cell carcinoma.

Authors:  Shao-Bin Chen; Hong-Rui Weng; Geng Wang; Xiao-Fang Zou; Di-Tian Liu; Yu-Ping Chen; Hao Zhang
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

8.  Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients.

Authors:  Onur C Kutlu; Mitchell Watchell; Sharmila Dissanaike
Journal:  Surg Oncol       Date:  2015-03-24       Impact factor: 3.279

9.  Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer.

Authors:  Ching-Feng Wu; Ching-Yang Wu; Jui-Ying Fu; Chi-Wei Wang; Yun-Hen Liu; Ming-Ju Hsieh; Yi-Cheng Wu
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

10.  Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer.

Authors:  Han-xiang Zhan; Jian-wei Xu; Lei Wang; Guang-yong Zhang; San-yuan Hu
Journal:  World J Surg Oncol       Date:  2015-03-13       Impact factor: 2.754

View more
  6 in total

1.  Metastatic lymph node ratio and Lauren classification are independent prognostic markers for survival rates of patients with gastric cancer.

Authors:  Huan Wang; Xiao-Ming Xing; Lei-Na Ma; Lian Liu; Jing Hao; Ling-Xin Feng; Zhuang Yu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

2.  Pathologic lymph node ratio is a predictor of esophageal carcinoma patient survival: a literature-based pooled analysis.

Authors:  Yuming Zhao; Shengyi Zhong; Zhenhua Li; Xiaofeng Zhu; Feima Wu; Yanxing Li
Journal:  Oncotarget       Date:  2017-07-15

3.  Prognostic role of the lymph node ratio in node positive colorectal cancer: a meta-analysis.

Authors:  Ming-Ran Zhang; Tian-Hang Xie; Jun-Lin Chi; Yuan Li; Lie Yang; Yong-Yang Yu; Xiao-Feng Sun; Zong-Guang Zhou
Journal:  Oncotarget       Date:  2016-11-08

4.  The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis.

Authors:  Liu Kai; Chen Zhoumiao; Xu Shaohua; Chen Zhao; Li Zhijun; He Zhengfu; Cai Xiujun
Journal:  J Cardiothorac Surg       Date:  2021-01-19       Impact factor: 1.637

5.  Metastatic lymph node ratio demonstrates better prognostic stratification than pN staging in patients with esophageal squamous cell carcinoma after esophagectomy.

Authors:  Hongdian Zhang; Huagang Liang; Yongyin Gao; Xiaobin Shang; Lei Gong; Zhao Ma; Ke Sun; Peng Tang; Zhentao Yu
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

6.  Prognostic value of number of negative lymph node in patients with stage II and IIIa non-small cell lung cancer.

Authors:  Shengguang Wang; Bin Zhang; Chenguang Li; Chao Cui; Dongsheng Yue; Bowen Shi; Qiang Zhang; Zhenfa Zhang; Xi Zhang; Changli Wang
Journal:  Oncotarget       Date:  2017-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.